Letermovir injection and preparation method thereof
Through dry mixing and multi-stage filtering methods, the problem of inconsistency in bubbles and particle sizes in the preparation of letemovir injection was solved, the stability and quality consistency of the product were improved, and the replacement of the original preparation was achieved, and the simplification of the simplification of the Process flow and reduce costs.
Patent Information
- Application Number
- CN202411188917.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-28
AI Technical Summary
During the preparation of letemovir injection, bubbles, emulsion and particle size are easily inconsistent, which affects product quality and efficacy, and is difficult to be consistent with the original preparation.
Dry mixing to form a mixed powder, hydroxypropyl-β-cyclodextrin and sodium hydroxide, and dissolved in injection water from 40°C to 70°C, filtered and terminalized through a multi-stage polyethersulfone filter element. Sterilization, simplify process flow, and improve production efficiency.
The problem of inconsistent bubbles, emulsion and particle size is solved, the stability and quality consistency of the product are improved, the effective replacement of the original formulation is achieved, the process flow is simplified, and the production cost is reduced.
Smart Images

Figure BDA0005014458340000041 
Figure BDA0005014458340000051 
Figure BDA0005014458340000061
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pharmaceutical preparations, and in particular to a Letermovir injection and a preparation method thereof. Background Art
[0002] Letermovir injection is a new type of non-nucleoside cytomegalovirus (CMV) inhibitor developed by Merck. It effectively blocks the processing and packaging of viral DNA by targeting the viral terminal enzyme complex, thereby exerting an antiviral effect. Letermovir has high selectivity and potent effects on CMV, and has higher selectivity and intensity of action compared with DNA polymerase inhibitors. Clinical studies have shown that letermovir can effectively prevent CMV infection in patients, and has no obvious adverse reactions such as bone marrow suppression and increased nephrotoxicity, and no restrictions on cross-resistance. The two dosage forms of letermovir (tablets and injection) can be used interchangeably, and there is no need to adjust the dose when changing, providing a personalized prevention plan for the clinic. Letermovir injection is suitable for patients who cannot take oral medications, especially adult recipients with positive CMV serology after allogeneic hematopoietic stem cell transplantation (allo-HSCT), for the prevention of CMV infection and CMV disease. Letermovir injection was approved for marketing in China in May 2022. Prior to this, letermovir tablets were approved in China in January 2022.
[0003] According to the instructions of the original reference preparation, the letermovir injection contains hydroxypropyl-β-cyclodextrin (HP-β-CD) as a cosolvent, and sodium hydroxide is added to adjust the pH value. The conventional preparation methods of cyclodextrin inclusion compounds generally include precipitation method and coprecipitation method. Since letermovir is almost insoluble in water and easily floats on the surface of the liquid, stable bubbles will be generated when stirred, and opalescence is easily generated. Therefore, the preparation of letermovir injection is difficult. The use of sodium hydroxide as a solubilizer can reduce the difficulty of preparation. However, the particle size peak position of the prepared sample is inconsistent with the original reference, which affects the inclusion effect of HP-β-CD and may cause differences in quality and clinical efficacy. Therefore, it is difficult to prepare a letermovir injection with the same quality as the original research by conventional methods. Summary of the invention
[0004] In view of this, the present invention provides a letermovir injection and a preparation method thereof. The present invention directly dry-mixes letermovir, hydroxypropyl-β-cyclodextrin and sodium hydroxide to obtain a mixed powder, and then adds the mixed powder to water for injection, thereby solving the problems of bubbles and opalescence being easily generated during the preparation of letermovir injection, and the particle size being inconsistent with the original preparation, and the injection has high stability, and can effectively replace the original preparation.
[0005] In order to achieve the above object, the technical solution provided by the present invention is:
[0006] The present invention provides a method for preparing a letermovir injection, comprising the following steps:
[0007] Step a, weighing letermovir, hydroxypropyl-β-cyclodextrin and sodium hydroxide according to the prescribed amount, mixing them evenly to obtain a mixed powder;
[0008] Step b, adding the mixed powder to a portion of water for injection, dissolving it, and adding water for injection to the total amount to obtain a Letermovir solution;
[0009] Step c, filtering the Letermovir solution through a multi-stage polyethersulfone filter element with successively decreasing pore sizes, filling, sealing, and sterilizing to obtain a Letermovir injection;
[0010] Wherein, in step b, the temperature of the water for injection is 40°C to 70°C.
[0011] The inventor accidentally discovered through a large number of experiments that after directly mixing the prescription amount of letermovir, hydroxypropyl-β-cyclodextrin and sodium hydroxide with a dry powder once, and then adding it to the injection water at a temperature of 40°C to 70°C for stirring and dissolving, letermovir can easily enter below the liquid surface to dissolve, and will not float on the surface of the liquid surface to adhere to the preparation container, and no bubbles are generated during the stirring process. At the same time, since the mixed materials of this method are completely dissolved in the injection water, no large particle size aggregates will be generated. Therefore, the prepared letermovir injection has no opalescence phenomenon, and the particle size peak of the prepared product is consistent with the original research. It has been proved through long-term stability tests that the letermovir injection prepared by the present invention has stable properties and content under long-term test conditions, no opalescence and precipitation, which helps to improve the efficacy and drug safety of letermovir injection, thereby achieving effective substitution for the original research.
[0012] Furthermore, in step a, the uniform mixing is performed using a dry mixer.
[0013] The present invention adopts a one-step dry mixing and one-step feeding method, which greatly improves production efficiency, simplifies the process flow, and facilitates industrial-scale production and application.
[0014] Exemplarily, in step a, the stirring speed of the dry mixer is 100 r / min to 200 r / min, and the mixing time is 15 min to 30 min.
[0015] Furthermore, in step b, the portion of water for injection is 40% to 70% of the total preparation amount.
[0016] After using a one-step dry mixing method, letermovir can directly enter below the liquid surface and dissolve completely. There is no precipitation of insoluble particles and no opalescence in the prepared product. The product quality is consistent with the original research. This provides a simple and efficient new method for letermovir injection, which is of great significance for expanding the application of letermovir.
[0017] Furthermore, the multi-stage filter element filtration is a two-stage polyethersulfone filter element filtration, wherein the pore size of the first-stage polyethersulfone filter element is 0.45 μm, and the pore size of the second-stage polyethersulfone filter element is 0.2 μm.
[0018] The invention adopts multi-stage polyethersulfone filter elements with specific pore sizes for sequential filtration, ensuring that the bacteria and endotoxin content of the product are qualified; no activated carbon is used in the production process, which reduces the pollution to the production clean area, alleviates the environmental pressure, and also reduces the impurities and insoluble particles that may be introduced by activated carbon, which is conducive to further improving the effectiveness, safety and stability of product quality.
[0019] Furthermore, in step c, the sterilization is performed at 121° C. for 8 min to 15 min.
[0020] The present invention adopts a terminal sterilization method to improve the aseptic level and sterilization efficiency of the product.
[0021] The preparation method of the letermovir injection provided by the present invention has simple process operation, and only needs to control the mixing mode of materials, and the letermovir injection with the same quality as the original product can be prepared by one-time feeding. At the same time, the present invention adopts a terminal sterilization method, and does not use activated carbon in the preparation process, which greatly improves the safety of the clinical use of the product, reduces the production cost, and has broad application prospects.
[0022] The present invention also provides a Letermovir injection, which is prepared by any of the above methods for preparing Letermovir injection.
[0023] Furthermore, each 1 mL of the Letermovir injection comprises: 20 mg of Letermovir, 145 mg to 155 mg of hydroxypropyl-β-cyclodextrin, 1 mg to 1.5 mg of sodium hydroxide and 3 mg to 3.5 mg of sodium chloride.
[0024] Preferably, each 1 mL of the Letermovir injection comprises: 20 mg Letermovir, 140 mg hydroxypropyl-β-cyclodextrin, 1.2 mg sodium hydroxide and 3.1 mg sodium chloride.
[0025] Furthermore, the specifications of the Letermovir injection are 12mL: 240mg and 24mL: 480mg.
[0026] The preparation method of the letermovir injection provided by the present invention effectively reduces the difficulty of preparing the letermovir injection, is simple to operate, does not require special equipment, has high industrial feasibility, and the prepared letermovir injection has high quality stability, a total impurity content of ≤0.15% over a long period of 12 months, and an increase in impurity content is significantly reduced during storage. The property is always a colorless clear solution, and the pH value is stable, which is beneficial to improving the safety of the clinical application of the letermovir injection, can achieve effective substitution for the original research, and has broad application prospects. DETAILED DESCRIPTION
[0027] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0028] In order to better illustrate the present invention, further examples are given below.
[0029] Example 1
[0030] This embodiment provides a letermovir injection, and the prescription dosage is as follows:
[0031]
[0032] Water for injection to 1 mL.
[0033] The specific preparation steps are as follows:
[0034] Step a, weighing letermovir, hydroxypropyl-β-cyclodextrin, sodium hydroxide and sodium chloride according to the prepared amounts, adding them into a dry powder mixer, and stirring and mixing at 180 r / min for 20 min to obtain a mixed powder;
[0035] Step b, adding the mixed powder to 40° C. water for injection, which accounts for 40% of the total amount, stirring and dissolving for 40 minutes, cooling to room temperature, and adding water for injection to the total amount to obtain a letermovir solution;
[0036] Step c, filtering the Letermovir solution through a two-stage polyethersulfone filter element, wherein the pore size of the first-stage polyethersulfone filter element is 0.45 μm, and the pore size of the second-stage polyethersulfone filter element is 0.2 μm, and then filling, sealing, and sterilizing at 121° C. for 10 minutes to obtain Letermovir injection.
[0037] The particle size of the prepared Letermovir injection was tested, and the scanning showed two nanometer particle size peaks, with peak positions of 1.73 nm and 401 nm. No precipitation or white spots were found after being placed at low temperature (2-8° C.) for 10 days.
[0038] The original (Merk Wharp, batch number: W029059) reference preparation scan showed two nanoparticle size peaks, peak positions: 1.78nm and 415nm. Small white spots precipitated after being placed at low temperature (2-8°C) for 5 days.
[0039] Example 2
[0040] This embodiment provides a letermovir injection, and the prescription dosage is as follows:
[0041]
[0042] Water for injection to 1 mL.
[0043] The specific preparation steps are as follows:
[0044] Step a, weighing letermovir, hydroxypropyl-β-cyclodextrin, sodium hydroxide and sodium chloride according to the prepared amounts, adding them into a dry powder mixer, and stirring and mixing at 100 r / min for 30 minutes to obtain a mixed powder;
[0045] Step b, adding the mixed powder to 50% of the total amount of injection water at 55°C, stirring and dissolving for 30 minutes, cooling to room temperature, and adding injection water to the total amount of preparation to obtain a letermovir solution;
[0046] Step c, filtering the Letermovir solution through a two-stage polyethersulfone filter element, wherein the pore size of the first-stage polyethersulfone filter element is 0.45 μm, and the pore size of the second-stage polyethersulfone filter element is 0.2 μm, and then filling, sealing, and sterilizing at 121° C. for 12 minutes to obtain Letermovir injection.
[0047] The particle size of the prepared Letermovir injection was tested, and the scanning showed two nanometer particle size peaks, with peak positions of 1.68 nm and 410 nm. No precipitation or white spots were found after being placed at low temperature (2-8° C.) for 10 days.
[0048] Example 3
[0049] This embodiment provides a letermovir injection, and the prescription dosage is as follows:
[0050]
[0051] Water for injection to 1 mL.
[0052] The specific preparation steps are as follows:
[0053] Step a, weighing letermovir, hydroxypropyl-β-cyclodextrin, sodium hydroxide and sodium chloride according to the prepared amounts, adding them into a dry powder mixer, and stirring and mixing at 150 r / min for 20 min to obtain a mixed powder;
[0054] Step b, adding the mixed powder to 45% of the total amount of water for injection at 65°C, stirring and dissolving for 25 minutes, cooling to room temperature, and adding water for injection to the total amount of the preparation to obtain a letermovir solution;
[0055] Step c, filtering the Letermovir solution through a two-stage polyethersulfone filter element, wherein the pore size of the first-stage polyethersulfone filter element is 0.45 μm, and the pore size of the second-stage polyethersulfone filter element is 0.2 μm, and then filling, sealing, and sterilizing at 121° C. for 12 minutes to obtain Letermovir injection.
[0056] The particle size of the prepared Letermovir injection was tested, and the scanning showed two nanometer particle size peaks, with peak positions of 1.78 nm and 426 nm. No precipitation or white spots were found after being placed at low temperature (2-8° C.) for 10 days.
[0057] Example 4
[0058] This embodiment provides a letermovir injection, and the prescription dosage is as follows:
[0059]
[0060] Water for injection to 1 mL.
[0061] The specific preparation steps are as follows:
[0062] Step a, weighing letermovir, hydroxypropyl-β-cyclodextrin, sodium hydroxide and sodium chloride according to the prepared amounts, adding them into a dry powder mixer, and stirring and mixing at 200 r / min for 15 minutes to obtain a mixed powder;
[0063] Step b, adding the mixed powder to 70° C. water for injection, which accounts for 70% of the total amount, stirring and dissolving for 25 minutes, cooling to room temperature, and adding water for injection to the total amount to obtain a letermovir solution;
[0064] Step c, filtering the Letermovir solution through a two-stage polyethersulfone filter element, wherein the pore size of the first-stage polyethersulfone filter element is 0.45 μm, and the pore size of the second-stage polyethersulfone filter element is 0.2 μm, and then filling, sealing, and sterilizing at 121° C. for 10 minutes to obtain Letermovir injection.
[0065] The particle size of the prepared Letermovir injection was tested, and the scanning showed two nanometer particle size peaks, with peak positions of 1.82 nm and 396 nm. No precipitation or white spots were found after being placed at low temperature (2-8° C.) for 10 days.
[0066] The samples of Letermovir injection prepared in Examples 1 to 4 and the reference preparation were sterilized again at 121° C. for 12 min, and then quality tested. The results are shown in Table 1.
[0067] Content detection method: Determine according to high performance liquid chromatography (Appendix VD of Part II of the 2010 edition of the Chinese Pharmacopoeia). Chromatographic column: octadecylsilane bonded silica gel chromatographic column; mobile phase: phosphoric acid-water-methanol = 3:247:750; detection wavelength: 274nm; flow rate: 1.5mL / min; column temperature: 30℃; injection volume: 1μL.
[0068] Related substance detection method: Determined according to high performance liquid chromatography (Appendix VD of Part II of the 2010 edition of the Chinese Pharmacopoeia). Chromatographic column: octadecylsilane bonded silica gel chromatographic column; mobile phase: water (pH adjusted to 2.5 with phosphoric acid)-acetonitrile = 1340:680; detection wavelength: 234nm; flow rate 2mL / min; column temperature: 30℃; injection volume: 1μL.
[0069] Table 1
[0070]
[0071]
[0072] The results showed that the properties, the presence or absence of precipitation and opalescence, and related substances of the Letermovir injection prepared in the example of the present invention were consistent with those of the reference preparation.
[0073] Long-term stability test
[0074] Examples 1 to 3 (sterilized once) and the reference preparation (batch number: W029059) were subjected to a long-term stability test at a temperature of 25°C ± 2°C and a relative humidity of 60% ± 10%. Samples were taken for testing at 0 months, 6 months, and 12 months, and the results are shown in Table 2.
[0075] Table 2
[0076]
[0077]
[0078] The results show that the Letermovir injection prepared in the embodiment of the present invention has good stability and is consistent with the original research, and can effectively replace the original research.
[0079] The Letermovir injection prepared in Example 4 can achieve the same technical effects as those in Examples 1 to 3.
[0080] Comparative Example 1
[0081] This comparative example provides a letermovir injection, the formula of which is exactly the same as that of Example 1, and the preparation method comprises the following steps:
[0082] Step a, weighing sodium hydroxide according to the prepared amount, adding it to 45% of the total amount of 55° C. water for injection, stirring and dissolving to obtain a sodium hydroxide solution;
[0083] Step b, adding a prepared amount of hydroxypropyl-β-cyclodextrin to the above sodium hydroxide solution, stirring to dissolve, then adding a prepared amount of letermovir, vigorously stirring for 30 minutes, adding a prepared amount of sodium chloride, stirring for 35 minutes to dissolve, to obtain a letermovir solution;
[0084] Step c, adding activated carbon to the above-mentioned letermovir injection, stirring to remove pyrogens, filtering to remove the activated carbon, and obtaining a filtrate; filtering the filtrate with 0.45 μm and 0.2 μm polyethersulfone filter elements in sequence, filling, and sterilizing at 121° C. for 12 minutes to obtain letermovir injection.
[0085] During the preparation process, it was found that a small amount of Letermovir still floated on the liquid surface and the tank wall, and the solution had a light blue opalescent luster. After the addition of activated carbon treatment, the liquid became clear and had an opalescent luster after sterilization.
[0086] At the same time, the scan showed that the Letermovir injection prepared in this comparative example had three particle size peaks: 1.23 nm, 171 nm and 568 nm, and white spots precipitated after being left at room temperature overnight.
[0087] Comparative Example 2
[0088] This comparative example provides a letermovir injection, the formula of which is exactly the same as that of Example 1, and the preparation method comprises the following steps:
[0089] Step a, weighing sodium hydroxide according to the prepared amount, adding it to 65% of the total amount of 50° C. water for injection, stirring and dissolving to obtain a sodium hydroxide solution;
[0090] Step b, adding a prepared amount of letermovir to the above sodium hydroxide solution, vigorously stirring for 30 minutes, then adding a prepared amount of sodium chloride, stirring for 35 minutes to dissolve, and finally adding a prepared amount of hydroxypropyl-β-cyclodextrin, stirring to dissolve, to obtain a letermovir solution;
[0091] Step c, adding activated carbon to the above-mentioned letermovir injection, stirring to remove pyrogens, filtering to remove the activated carbon, and obtaining a filtrate; filtering the filtrate with 0.45 μm and 0.2 μm polyethersulfone filter elements in sequence, filling, and sterilizing at 121° C. for 12 minutes to obtain letermovir injection.
[0092] During the preparation process, it was found that after adding letermovir and stirring vigorously for 30 minutes, a small part was still floating on the liquid surface and the tank wall, and there were insoluble small particles in the solution. After adding hydroxypropyl-β-cyclodextrin and stirring to dissolve, the solution showed a light blue opalescence.
[0093] At the same time, the scan showed that the Letermovir injection prepared in this comparative example had three particle size peaks: 2.93nm, 275nm and 4560nm, and white spots precipitated after being left at room temperature overnight.
[0094] Comparative Example 3
[0095] This comparative example provides a method for preparing Letermovir injection, and the specific steps are as follows:
[0096] Step a, weighing 18.0 g of arginine, adding 160 mL of water for injection to completely dissolve it, to obtain an arginine aqueous solution;
[0097] Step b, dissolving 20 g of letermovir in the above arginine aqueous solution, adding 6 g of sodium acetate trihydrate, stirring and dissolving; adding sodium hydroxide to adjust the pH to 5.7, adding 40 mL of water for injection to the total amount, to obtain letermovir solution;
[0098] Step c, adding activated carbon to the above-mentioned letermovir solution, stirring to remove pyrogens, filtering to remove the activated carbon, and obtaining a filtrate; filtering the filtrate with 0.45 μm and 0.2 μm polyethersulfone filter elements in sequence, and filling to obtain a letermovir injection.
[0099] The Letermovir injection prepared in Example 1 and Comparative Example 3 and the reference preparation were sterilized at 121° C. for 12 min, respectively, and quality tests were performed. The results are shown in Table 3.
[0100] Table 3
[0101]
[0102] The results show that the impurity content of Comparative Example 3 and the reference preparation increased significantly after secondary sterilization; at the same time, the total impurities of Comparative Example 3 after sterilization significantly exceeded those of the reference preparation and the sample prepared in Example 1 of the present invention.
[0103] In summary, the present invention adopts a direct mixing one-step feeding method to prepare letermovir injection, which significantly shortens the preparation time and avoids the problems of bubbles, wall adhesion, opalescence and precipitation in the preparation process, is conducive to scale-up production and improve product quality, increases the preparation success rate, and effectively improves the safety of clinical use, which has practical social significance and economic value.
[0104] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for preparing letermovir injection, It is characterized in that The steps include: Step a, weighing letermovir, hydroxypropyl-β-cyclodextrin and sodium hydroxide according to the prescribed amount, mixing them evenly to obtain a mixed powder; Step b, adding the mixed powder to a portion of water for injection, dissolving it, and adding water for injection to the total amount to obtain a Letermovir solution; Step c, filtering the Letermovir solution through a multi-stage polyethersulfone filter element with successively decreasing pore sizes, filling, sealing, and sterilizing to obtain a Letermovir injection; Wherein, in step b, the temperature of the water for injection is 40°C to 70°C.
2. The method for preparing the Letermovir injection according to claim 1, It is characterized in that In step a, the mixing is carried out uniformly by using a dry mixer.
3. The method for preparing the Letermovir injection according to claim 1, It is characterized in that In step b, the part of water for injection accounts for 40% to 70% of the total preparation amount.
4. The method for preparing the Letermovir injection according to claim 1, It is characterized in that The multi-stage filter element filtration is a two-stage polyethersulfone filter element filtration, wherein the pore size of the first-stage polyethersulfone filter element is 0.45 μm, and the pore size of the second-stage polyethersulfone filter element is 0.2 μm.
5. The method for preparing Letermovir injection according to claim 1, It is characterized in that In step c, the sterilization is performed at 121° C. for 8 to 15 minutes.
6. A letermovir injection, It is characterized in that The Letermovir injection is prepared by the preparation method of any one of claims 1 to 5.
7. The Letermovir injection according to claim 6, It is characterized in that Each 1 mL of the letermovir injection includes: 20 mg of letermovir, 145 mg to 155 mg of hydroxypropyl-β-cyclodextrin, 1 mg to 1.5 mg of sodium hydroxide and 3 mg to 3.5 mg of sodium chloride.
8. The Letermovir injection according to claim 7, It is characterized in that Each 1 mL of the Letermovir injection includes: 20 mg of Letermovir, 140 mg of hydroxypropyl-β-cyclodextrin, 1.2 mg of sodium hydroxide and 3.1 mg of sodium chloride.
9. The Letermovir injection according to any one of claims 6 to 8, It is characterized in that The specifications of the Letermovir injection are 12mL:240mg and 24mL:480mg.
Citation Information
Patent Citations
Method for dissolving flavonoid compounds, carbon glycoside compounds or stilbene compounds and preparation method of injection or injectable powder injection
CN103356476A
Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
US20150133461A1
